Search

Your search keyword '"Estrella, Hayley"' showing total 7 results
Start Over Author "Estrella, Hayley"
7 results on '"Estrella, Hayley"'

1. Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies

Author

O'Reilly, Eileen A., primary, Lohrmann, Christian, additional, O'Donoghue, Joseph A., additional, Borazanci, Erkut, additional, Estrella, Hayley, additional, Teng, Rebecca, additional, Melink, Terri, additional, Dorr, Kirsten, additional, Kearns, Christine, additional, Peterson, Marvin, additional, Ostrowski, Jack, additional, Gutheil, John, additional, Maffuid, Paul W., additional, Lewis, Jason S., additional, and Weber, Wolfgang, additional

Published
2018
Full Text
View/download PDF

2. HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

Author

O'Reilly, Eileen Mary, primary, Borazanci, Erkut Hasan, additional, Yu, Kenneth H., additional, Varghese, Anna M., additional, Estrella, Hayley, additional, Kamins, David, additional, Melink, Teresa, additional, Dorr, Kirsten, additional, Maffuid, Paul, additional, Gutheil, John, additional, Wang, Judy Sing-Zan, additional, and Bauer, Todd Michael, additional

Published
2018
Full Text
View/download PDF

3. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: GermlineBRCAmutation carriers and wild-typeBRCApancreatic ductal adenocarcinoma

Author

O'Reilly, Eileen M., primary, Lee, Jonathan W., additional, Lowery, Maeve A., additional, Capanu, Marinela, additional, Stadler, Zsofia K., additional, Moore, Malcolm J., additional, Dhani, Neesha, additional, Kindler, Hedy L., additional, Estrella, Hayley, additional, Maynard, Hannah, additional, Golan, Talia, additional, Segal, Amiel, additional, Salo-Mullen, Erin E., additional, Yu, Kenneth H., additional, Epstein, Andrew S., additional, Segal, Michal, additional, Brenner, Robin, additional, Do, Richard K., additional, Chen, Alice P., additional, Tang, Laura H., additional, and Kelsen, David P., additional

Published
2018
Full Text
View/download PDF

4. Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Author

O'Reilly, Eileen Mary, primary, Wang, Judy Sing-Zan, additional, Yu, Kenneth H., additional, Lowery, Maeve Aine, additional, Varghese, Anna M., additional, Bendell, Johanna C., additional, Borazanci, Erkut Hasan, additional, Estrella, Hayley, additional, Fowler, Kimberly, additional, Hoskins, Mariella, additional, Bussen, Stephanie, additional, Melink, Teresa J., additional, Kearns, Christine M., additional, Jun, H Toni, additional, Maffuid, Paul W., additional, Gutheil, John C., additional, and Bauer, Todd Michael, additional

Published
2018
Full Text
View/download PDF

5. Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics.

Author

Jordan, Emmet, primary, Kaley, Thomas Joseph, additional, Capanu, Marinela, additional, Estrella, Hayley, additional, Leach, Steven D, additional, Basturk, Olca, additional, Klimstra, David S., additional, Allen, Peter J., additional, Berger, Michael F., additional, Yu, Kenneth H., additional, Lowery, Maeve Aine, additional, and O'Reilly, Eileen Mary, additional

Published
2017
Full Text
View/download PDF

6. Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.

Author

O'Reilly, Eileen Mary, primary, Wang, Judy Sing-Zan, additional, Yu, Kenneth H., additional, Lowery, Maeve Aine, additional, Varghese, Anna M., additional, Bendell, Johanna C., additional, Borazanci, Erkut Hasan, additional, Estrella, Hayley, additional, Fowler, Kimberly, additional, Hoskin, Mariella, additional, Jun, H. Toni, additional, Melink, Teresa J., additional, Maffuid, Paul, additional, Klein, Pamela, additional, Gutheil, John, additional, and Bauer, Todd Michael, additional

Published
2017
Full Text
View/download PDF

7. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

Author

O'Reilly, Eileen M., Lee, Jonathan W., Lowery, Maeve A., Capanu, Marinela, Stadler, Zsofia K., Moore, Malcolm J., Dhani, Neesha, Kindler, Hedy L., Estrella, Hayley, Maynard, Hannah, Golan, Talia, Segal, Amiel, Salo‐Mullen, Erin E., Yu, Kenneth H., Epstein, Andrew S., Segal, Michal, Brenner, Robin, Do, Richard K., Chen, Alice P., and Tang, Laura H.

Subjects
CISPLATIN, GERM cells, ADENOCARCINOMA, ANTINEOPLASTIC agents, PANCREATIC tumors, TUMOR treatment
Abstract

Background: A phase 1 trial was used to evaluate a combination of cisplatin, gemcitabine, and escalating doses of veliparib in patients with untreated advanced pancreatic ductal adenocarcinoma (PDAC) in 2 cohorts: a germline BRCA1/2-mutated (BRCA+) cohort and a wild-type BRCA (BRCA-) cohort. The aims were to determine the safety, dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase 2 dose (RP2D) of veliparib combined with cisplatin and gemcitabine and to assess the antitumor efficacy (Response Evaluation Criteria in Solid Tumors, version 1.1) and overall survival.Methods: Gemcitabine and cisplatin were dosed at 600 and 25 mg/m2 , respectively, over 30 minutes on days 3 and 10 of a 21-day cycle. Four dose levels of veliparib were evaluated: 20 (dose level 0), 40 (dose level 1), and 80 mg (dose level 2) given orally twice daily on days 1 to 12 and 80 mg given twice daily on days 1 to 21 (dose level 2A [DL2A]).Results: Seventeen patients were enrolled: 9 BRCA+ patients, 7 BRCA- patients, and 1 patient with an unknown status. DLTs were reached at DL2A (80 mg twice daily on days 1 to 21). Two of the 5 patients in this cohort (40%) experienced grade 4 neutropenia and thrombocytopenia. Two grade 5 events occurred on protocol. The objective response rate in the BRCA+ cohort was 7 of 9 (77.8%). The median overall survival for BRCA+ patients was 23.3 months (95% confidence interval [CI], 3.8-30.2 months). The median overall survival for BRCA- patients was 11 months (95% CI, 1.5-12.1 months).Conclusions: The RP2D of veliparib was 80 mg by mouth twice daily on days 1 to 12 in combination with cisplatin and gemcitabine; the DLT was myelosuppression. Substantial antitumor activity was seen in BRCA+ PDAC. A randomized phase 2 trial is currently evaluating cisplatin and gemcitabine with and without veliparib for BRCA+ PDAC (NCT01585805). Cancer 2018;124:1374-82. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results